Evidence map›Paper›PMID 36194754›Full record

ArticleJournal of the American Chemical Society2022

Characterization of a Radical SAM Oxygenase for the Ether Crosslinking in Darobactin Biosynthesis.

Hai Nguyen, I Dewa Made Kresna, Nils Böhringer, Jeremie Ruel, Eugenio de la Mora, Jil-Christine Kramer, Kim Lewis, Yvain Nicolet, Till F Schäberle, Kenichi Yokoyama

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Synthetic Studies Towards Darobactin A.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  3. RadicalJournal of the American Chemical Society · 2026
    Article
  4. Biosynthesis of the Biphenomycin Family of Potent Antibiotics.Angewandte Chemie (International ed. in English) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Hai NguyenDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina 27710, United States.
I Dewa Made KresnaInstitute for Insect Biotechnology, Justus-Liebig-University of Giessen, Ohlebergsweg 12, 35392 Giessen, Germany.
Nils BöhringerInstitute for Insect Biotechnology, Justus-Liebig-University of Giessen, Ohlebergsweg 12, 35392 Giessen, Germany.
Jeremie RuelUniversity of Grenoble Alpes, CEA, CNRS, IBS, Metalloproteins Unit, F-38000 Grenoble, France.
Eugenio de la MoraUniversity of Grenoble Alpes, CEA, CNRS, IBS, Metalloproteins Unit, F-38000 Grenoble, France.
Jil-Christine KramerInstitute for Insect Biotechnology, Justus-Liebig-University of Giessen, Ohlebergsweg 12, 35392 Giessen, Germany.
Kim LewisAntimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, Massachusetts 02115, United States.
Yvain NicoletUniversity of Grenoble Alpes, CEA, CNRS, IBS, Metalloproteins Unit, F-38000 Grenoble, France.ORCID 0000-0002-4189-7067
Till F SchäberleInstitute for Insect Biotechnology, Justus-Liebig-University of Giessen, Ohlebergsweg 12, 35392 Giessen, Germany.ORCID 0000-0001-9947-8079
Kenichi YokoyamaDepartment of Biochemistry, Duke University School of Medicine, Durham, North Carolina 27710, United States.ORCID 0000-0001-5625-469X
Justus-Liebig-Universität Gießen · DECentre National de la Recherche Scientifique · FRDuke University · USNortheastern University · US

Funding

Evaluating darobactins as antimicrobial agentsR01AI158388 · NIAID · NORTHEASTERN UNIVERSITY · PI LEWIS, KIM · 2021 to 2025
$3.0M
Mechanism of cofactor biosynthesis required for chronic bacterial infectionR01GM112838 · NIGMS · DUKE UNIVERSITY · PI YOKOYAMA, KENICHI · 2015 to 2023
$2.8M
NIAID NIH HHS R01 AI158388NIGMS NIH HHS R01 GM112838
6 · The paper itself

Abstract

Darobactin A is a ribosomally synthesized, post-translationally modified peptide (RiPP) with potent and broad-spectrum anti-Gram-negative antibiotic activity. The structure of darobactin A is characterized by an ether and C-C crosslinking. However, the specific mechanism of the crosslink formation, especially the ether crosslink, remains elusive. Here, using in vitro enzyme assays, we demonstrate that both crosslinks are formed by the DarE radical

Indexed as

EtherS-AdenosylmethionineAnti-Bacterial AgentsEthersOxygenOxygenasesPeptidesPhenylpropionatesWaterAnti-Bacterial AgentsdarobactinEtherEthersOxygenOxygenasesPeptidesPhenylpropionatesS-AdenosylmethionineWater

Identifiers

PMID36194754
PMCPMC9588720
OpenAlexW4301183052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.